Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention , 2020. február 11. [2020. március 4-i dátummal az eredetiből archiválva]. (Hozzáférés: 2020. március 11.)
Wu, Yi-Chi (2020. március 1.). „The outbreak of COVID-19: An overview”. Journal of the Chinese Medical Association83 (3), 217–220. o. DOI:10.1097/JCMA.0000000000000270. ISSN1726-4901.
(2020. február 1.) „Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province”. Chinese Medical Journal, 1. o. DOI:10.1097/CM9.0000000000000744. PMID32044814.
(2020. március 1.) „Comorbidities and multi-organ injuries in the treatment of COVID–19”. Lancet395 (10228), e52. o, Kiadó: Elsevier BV. DOI:10.1016/s0140-6736(20)30558-4. PMID32171074.
Henry, Brandon Michael (2020. december 12.). „COVID–19, ECMO, and lymphopenia: a word of caution”. The Lancet Respiratory Medicine8 (4), e24. o, Kiadó: Elsevier BV. DOI:10.1016/s2213-2600(20)30119-3. ISSN2213-2600. PMID32178774.
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. W. (2003). „Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus” (angol nyelven). The Lancet361 (9374), 2045-2046. o. DOI:10.1016/s0140-6736(03)13615-x. PMID12814717.
Crance, J. M., Scaramozzino, N., Jouan, A., & Garin, D. (2003). „Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses” (angol nyelven). Antiviral research58 (1), 73-79. o. DOI:10.1016/s0166-3542(02)00185-7. PMID12719009.
Hoever, G., Baltina, L., Michaelis, M., Kondratenko, R., Baltina, L., Tolstikov, G. A., Cinatl, J. et al. (2005). „Antiviral Activity of Glycyrrhizic Acid Derivatives against SARS− Coronavirus” (angol nyelven). Journal of medicinal chemistry48 (4), 1256-1259. o. DOI:10.1021/jm0493008. PMID15715493.
Berencsi György, Takács Mária, Minárovits János: Vírusok, prionok és a vírusfertőzések megelőzése. eduvital.net. EDUVITAL Nonprofit Egészségnevelési Társaság. [2020. április 25-i dátummal az eredetiből archiválva]. (Hozzáférés: 2020. február 26.)
Gautret, et al. (2020.. 03.). „Hydroxychloroquine and Azithromycin as a treatment of COVID–19: preliminary results of an open-label non-randomized clinical trial”. medrxiv.org.Laikus összefoglaló „Background Chloroquine and Hydroxychloroquine have been found to be efficient on COV-19, and reported to be efficient in Chinese patients infected by this virus. We evaluate the role of Hydroxychloroquine on respiratory viral loads. Patients and methods Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily. Depending on their clinical presentation azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative control. Presence and absence of virus at Day-6 was considered the end point. Results Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D-6 compared to controls, and much lower than reported average carrying duration of untreated patients in the literature. Azithromycin added to Hydroxychloroquine was significantly more efficient for virus elimination. Conclusion : Hydroxychloroquine is significantly associated with viral load reduction/disappearance in patients with COVID–19 and its effect is reinforced by Azithromycin.”
Anthony S. Fauci, M.D., H. Clifford Lane, M.D., and Robert R. Redfield, M.D.: Covid-19 — Navigating the Uncharted (angol nyelven). nejm.org. New England Journal of Medicine, 2020. február 28. (Hozzáférés: 2020. március 10.)
(2020. február 1.) „Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province”. Chinese Medical Journal, 1. o. DOI:10.1097/CM9.0000000000000744. PMID32044814.
(2020. március 1.) „Comorbidities and multi-organ injuries in the treatment of COVID–19”. Lancet395 (10228), e52. o, Kiadó: Elsevier BV. DOI:10.1016/s0140-6736(20)30558-4. PMID32171074.
Henry, Brandon Michael (2020. december 12.). „COVID–19, ECMO, and lymphopenia: a word of caution”. The Lancet Respiratory Medicine8 (4), e24. o, Kiadó: Elsevier BV. DOI:10.1016/s2213-2600(20)30119-3. ISSN2213-2600. PMID32178774.
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. W. (2003). „Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus” (angol nyelven). The Lancet361 (9374), 2045-2046. o. DOI:10.1016/s0140-6736(03)13615-x. PMID12814717.
Crance, J. M., Scaramozzino, N., Jouan, A., & Garin, D. (2003). „Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses” (angol nyelven). Antiviral research58 (1), 73-79. o. DOI:10.1016/s0166-3542(02)00185-7. PMID12719009.
Hoever, G., Baltina, L., Michaelis, M., Kondratenko, R., Baltina, L., Tolstikov, G. A., Cinatl, J. et al. (2005). „Antiviral Activity of Glycyrrhizic Acid Derivatives against SARS− Coronavirus” (angol nyelven). Journal of medicinal chemistry48 (4), 1256-1259. o. DOI:10.1021/jm0493008. PMID15715493.
Berencsi György, Takács Mária, Minárovits János: Vírusok, prionok és a vírusfertőzések megelőzése. eduvital.net. EDUVITAL Nonprofit Egészségnevelési Társaság. [2020. április 25-i dátummal az eredetiből archiválva]. (Hozzáférés: 2020. február 26.)
Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention , 2020. február 11. [2020. március 4-i dátummal az eredetiből archiválva]. (Hozzáférés: 2020. március 11.)
Wu, Yi-Chi (2020. március 1.). „The outbreak of COVID-19: An overview”. Journal of the Chinese Medical Association83 (3), 217–220. o. DOI:10.1097/JCMA.0000000000000270. ISSN1726-4901.
Henry, Brandon Michael (2020. december 12.). „COVID–19, ECMO, and lymphopenia: a word of caution”. The Lancet Respiratory Medicine8 (4), e24. o, Kiadó: Elsevier BV. DOI:10.1016/s2213-2600(20)30119-3. ISSN2213-2600. PMID32178774.
